SecBot SecBot
DEFA14A ·Filed May 19, 2026

VXRT

Vaxart, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001213900-26-059087
Proxy solicitation materials
Actionable Insight ◆ Mixed

The proxy fight creates a binary catalyst: a management slate win maintains current strategy and clinical timeline; a dissident win introduces execution risk given nominees' lack of relevant experience. Monitor institutional shareholder voting intentions and any further dissident communications. The sentinel COVID-19 data release (Q2 2026) could shift sentiment ahead of the meeting.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.6100
T+0 close · May 19, 2026 · via day close
Latest settled
−10.90%
T+60 · $0.5435
Vs SPY
−15.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 20 $0.6100entry
  2. T+1 · 6mo ago +11.48%α +11.28% · $0.6800
  3. T+5 · 6mo ago +8.20%α +6.39% · $0.6600
  4. T+20 · 5mo ago −9.67%α −10.41% · $0.5510
  5. T+60 · 3mo ago −10.90%α −15.91% · $0.5435

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxart filed preliminary proxy materials and issued an open letter to shareholders ahead of its July 16, 2026 Annual Meeting, urging support for the incumbent Board against a dissident group that has nominated three candidates to replace half of the directors. Management emphasizes recent clinical progress (Phase 2b COVID-19 trial fully enrolled, norovirus and influenza programs advancing), a $61M cash runway into Q2 2027, and the addition of Dr. James Breitmeyer to the Board. The dissidents' nominees are characterized as lacking relevant public company, clinical-stage, or regulatory experience, making this a contested election with binary outcome risk for the company's strategic direction.

Key Financial Metrics

Vote
director election
Meeting
2026-07-16
Seats Contested
3

Key Facts

  • Annual Meeting scheduled for July 16, 2026; preliminary proxy materials filed May 19, 2026.
  • Dissident shareholders nominated three candidates to replace three of six Board seats.
  • Management added Dr. James Breitmeyer (35+ years clinical/regulatory experience) to the Board on April 23, 2026.
  • Phase 2b COVID-19 trial fully enrolled (~5,400 participants); sentinel 12-month safety data expected Q2 2026, primary readout early 2027.
  • Cash position ~$61M at Q1 2026 end; runway projected into Q2 2027.
  • CEO Steven Lo holds >2.5M shares and has never sold a share.
  • Dynavax/Sanofi partnership provides non-dilutive cash and milestone payments.
  • 21% workforce reduction and headquarters relocation completed in 2025.
  • $25M share purchase agreement in place for flexible capital access.

Financial Impact

No financial figures disclosed beyond ~$61M cash and $25M share purchase agreement. Dissident win could alter capital allocation and strategic direction.

cash runwaydilution riskstrategic direction

Risk Factors

  • Dissident nominees lack public company and clinical-stage experience, increasing execution risk if elected.
  • Phase 2b COVID-19 sentinel data (not powered for efficacy) may disappoint and weaken management's position.
  • Cash runway only into Q2 2027; additional dilutive financing likely needed regardless of board outcome.
  • Proxy contest could distract management from clinical milestones.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001213900-26-059087
Document: 0001213900-26-059087-index-headers.html0001213900-26-059087
Document: 0001213900-26-059087-index.html0001213900-26-059087
Document: 0001213900-26-059087.txt0001213900-26-059087

Track record

23 reports on VXRT

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
  2. Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
  3. Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
  4. Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
  5. Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
  6. Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
  7. Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
  8. Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  9. Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  10. Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 19, 2026